Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis - 04/03/21
Doi : 10.1016/j.jaci.2020.09.021
James G. Krueger, MD a 
, Dedee F. Murrell, MD b, Sandra Garcet, PhD a, Kristina Navrazhina, BA a, Patricia C. Lee, MD c, Elisa Muscianisi, MD d, Andrew Blauvelt, MD e
, Dedee F. Murrell, MD b, Sandra Garcet, PhD a, Kristina Navrazhina, BA a, Patricia C. Lee, MD c, Elisa Muscianisi, MD d, Andrew Blauvelt, MD e a Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY
b Department of Dermatology, St George Hospital, University of New South Wales, Sydney, Australia
c Center for Clinical Studies, Webster, Tex
d Novartis Pharmaceuticals Corporation, East Hanover, NJ
e the Oregon Medical Research Center, Portland, Ore
| This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Medical writing support was provided by the study sponsor. |
|
| Disclosure of potential conflict of interest: J.G. Krueger has received grants paid to The Rockefeller University from Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dermira, Innovaderm, Janssen, Kadmon, Kineta, Kyowa, LEO Pharma, Lilly, Novartis, Paraxel, Pfizer, Provectus, Regeneron, and Vitae and personal fees from AbbVie, Baxter, Biogen Idec, Boehringer Ingelheim, Bristol Myers Squibb, Delenex, Dermira, Janssen, Kadmon, Kineta, Lilly, Merck, Novartis, Pfizer, Sanofi, Serono, and XenoPort. D.F. Murrell has received grants from AbbVie, Novartis, Lilly, Dermira, Janssen, Menlo, Arcutis, Genentech, UCB, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB. P. Lee has received grants from and served as an investigator for AbbVie, Novartis, Maruho, Lilly, Celgene, Dermira, Janssen, Glenmark, Foamix, LEO Pharma, Menlo, Merck, Boehringer Ingelheim, Actavis, Arcutis, Bristol Myers Squibb, Genentech, UCB, and Regeneron. E. Muscianisi is an employee and stockholder of Novartis. A. Blauvelt has served as a scientific consultant and clinical study investigator for AbbVie, Aclaris, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Lilly, Forte, Galderma, Janssen, LEO Pharma, Novartis, Ortho, Pfizer, Rapt, Regeneron, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB and as a paid speaker for AbbVie. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 147 - N° 3
P. 1107 - Marzo 2021 Ritorno al numero
Articolo precedente
- Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom
- Luiza C. Campos, Giulia Di Colo, Vruti Dattani, Helen Braggins, Dinakantha Kumararatne, Anthony P. Williams, Hana Alachkar, Stephen Jolles, Alexandra Battersby, Theresa Cole, Suzanne Elcombe, Kimberly C. Gilmour, David Goldblatt, Andrew R. Gennery, Jamanda Haddock, David M. Lowe, Siobhan O. Burns
- Novel insights into the TRPV3-mediated itch in atopic dermatitis
- Ciara Larkin, Weiwei Chen, Imre Lőrinc Szabó, Chunxu Shan, Zsolt Dajnoki, Andrea Szegedi, Timo Buhl, Yuanyuan Fan, Sandra O'Neill, Dermot Walls, Wenke Cheng, Song Xiao, Jiafu Wang, Jianghui Meng
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?